HC Wainwright Predicts NeuroPace’s Q2 Earnings (NASDAQ:NPCE)

NeuroPace, Inc. (NASDAQ:NPCE) – HC Wainwright issued their Q2 2025 earnings estimates for shares of NeuroPace in a research report issued to clients and investors on Wednesday, May 28th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.22) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.82) EPS and FY2026 earnings at ($0.57) EPS.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $22.52 million for the quarter, compared to analysts’ expectations of $21.85 million.

NPCE has been the subject of several other reports. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

NeuroPace Stock Down 1.0%

NeuroPace stock opened at $12.98 on Friday. The stock has a market cap of $425.73 million, a price-to-earnings ratio of -12.98 and a beta of 2.04. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The company’s 50-day moving average price is $12.83 and its two-hundred day moving average price is $12.18. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.98.

Institutional Investors Weigh In On NeuroPace

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new stake in shares of NeuroPace in the 4th quarter valued at approximately $29,000. GAMMA Investing LLC acquired a new stake in shares of NeuroPace in the 1st quarter valued at approximately $53,000. Wells Fargo & Company MN boosted its holdings in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after buying an additional 2,279 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of NeuroPace in the 4th quarter valued at approximately $103,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of NeuroPace in the 4th quarter valued at approximately $112,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the business’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the transaction, the insider now directly owns 3,238,199 shares in the company, valued at approximately $51,325,454.15. The trade was a 4.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.